Magnera Introduces Innovative Solution for Healthcare and Beyond, Focusing on Safety and Sustainability

Rhea-AI Summary

Magnera (MAGN) launched a next-generation fluid-repellent solution for nonwoven textiles that delivers required protection without intentionally added PFAS. The product targets healthcare applications such as surgical gowns and drapes, claiming protection, comfort, and breathability while reducing potential pollutants.

The announcement cites accelerating regulatory action: the European Chemicals Agency expects final opinions on PFAS restrictions in 2026, and several U.S. states have enacted PFAS bans with compliance deadlines starting in 2025. Magnera positions the solution as a timely alternative amid supply shortages and rising costs for PFAS-containing materials.

Positive

• No intentionally added PFAS in the new textile solution
• Aligns with ECHA timeline expecting opinions in 2026
• Addresses state PFAS bans with compliance deadlines starting 2025

Negative

• Market facing supply shortages and rising costs for PFAS materials
• Regulatory timelines vary by jurisdiction, creating transitional uncertainty

CHARLOTTE, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Magnera, a leading supplier of advanced material solutions, today announced the launch of its next-generation solution for nonwoven textiles. Magnera’s proprietary innovation delivers fluid repellency needed by healthcare professionals and other industries without the use of per- and polyfluoroalkyl substances (PFAS).

PFAS have been widely used for decades in medical gowns, drapes, and other protective textiles due to their durability and resistance to water, oil, and stains. However, evidence of PFAS persistence in the environment and possible associated health risks has prompted global regulatory action and growing demand for alternatives.

Paul Harmon, Chief Innovation and Marketing Officer at Magnera, said: “Our new solution meets the industry’s stringent standards for protection, comfort, and compliance in articles such as surgical gowns or drapes, while reducing potential pollutants.”

Addressing a Global Challenge

Regulatory bodies worldwide are moving to restrict or reduce PFAS inclusion in manufacturing:

• The European Union: The European Chemicals Agency (ECHA) has published an updated proposal to restrict PFAS under the REACH regulation. The plan proposes phased bans and possible time-limited exemptions for essential uses, with final opinions expected in 2026 before requested implementation by the European Commission. (European Chemicals Agency, 2025).
• United States: Several states—including California, Maine, and Minnesota—have enacted laws banning the addition of PFAS in various consumer products, with some compliance deadlines starting in 2025. These bans target categories such as food packaging, textiles, cookware, and juvenile products. (Safer States, 2024).

As global manufacturers step away from solutions including PFAS, supply shortages and rising costs are accelerating the need for alternatives. Magnera’s innovation delivers a timely, future-ready solution for healthcare providers and other industries navigating this shift.

A Safer, Sustainable Alternative

Magnera’s Groundbreaking Solution Offers:

• High-performance fluid repellency without intentionally added PFAS
• Comfort and breathability for protective textiles
• Alignment with evolving global regulatory trends
• Increased Environmental responsibility

To learn more about Magnera’s solution, contact info@magnera.com or visit https://magnera.com/contact/

About Magnera

Magnera Corporation (NYSE: MAGN) serves 1,000+ customers worldwide, offering a wide range of material solutions, including components for absorbent hygiene products, protective apparel, wipes, specialty building and construction products, and products serving the food and beverage industry. Operating across 45 production facilities, Magnera is supported by over 8,500 global employees.

Magnera’s purpose is to better the world with new possibilities made real. For more than 160 years, the company has delivered the material solutions its partners need to thrive. Through economic upheaval, global pandemics, and changing end-user needs, we have consistently found ways to solve problems and exceed expectations. The distinct scale and comprehensive portfolio of products bring customers more materials and choices. Magnera builds personal partnerships that withstand an ever-changing world.

Visit magnera.com for more information and follow @MagneraCorporation on social platforms.

Forward-Looking Statements

Information included or incorporated by reference in Magnera Corporation’s filings with the U.S. Securities and Exchange Commission (the “SEC”) and press releases or other public statements contain or may contain “forward-looking” statements with the meaning of the federal securities laws and are presented pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such “forward-looking” statements include, but are not limited to, statements with respect to our financial condition, results of operations and business, our expectations or beliefs concerning future events, statements about future financial and operating results, the company’s plans, objectives, expectations and intentions and other statements that are not historical facts. These statements contain words such as “believes,” “expects,” “may,” “will,” “should,” “would,” “could,” “seeks,” “approximately,” “intends,” “plans,” “estimates,” “projects,” “outlook,” “anticipates,” or “looking forward” or similar expressions that relate to our strategy, plans, intentions or expectations. All statements we make relating to our estimated and projected earnings, margins, costs, expenditures, cash flows, growth rates, and financial results or to our expectations regarding future industry trends are forward-looking statements. In addition, we, through our senior management, from time to time make forward-looking public statements concerning our expected future operations and performance and other developments. These forward-looking statements are based upon the current beliefs and expectations of the management of Magnera and are subject to risks and uncertainties that may change at any time, and, therefore, our actual results may differ materially from those that we expected. These risks and other risk factors are detailed from time to time in Magnera’s reports filed with the SEC, including annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, including our Form 8-K/A filed on January 31, 2025, and other documents filed with the SEC. These risk factors may not contain all of the material factors that are important to you. New factors may emerge from time to time and it is not possible to either predict new factors or assess the potential effect of any such new factors. Accordingly, readers should not place undue reliance on those statements. All forward-looking statements are based upon information available as of the date hereof. All forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statements as a result of new information, future events, or otherwise, except as otherwise required by law.

References

1: European Chemicals Agency. (2025, August 20). ECHA publishes updated PFAS restriction proposal [Press release]. ECHA. https://echa.europa.eu/-/echa-publishes-updated-pfas-restriction-proposal
2: Safer States. (2024, July). State Action on PFAS in Consumer Products. Safer States. https://www.saferstates.org/resource/state-action-on-pfas/

Investor Contact:
Robert Weilminster
ir@magnera.com

Media Contact:
Kylee Agabashian
mediarelations@magnera.com

FAQ

What did Magnera (MAGN) announce on December 3, 2025 about PFAS-free textiles?

Magnera announced a next-generation nonwoven solution offering fluid repellency without intentionally added PFAS for healthcare and other industries.

How does Magnera's MAGN solution address healthcare protective textile needs?

The solution is designed to meet protection, comfort, and breathability standards for products like surgical gowns and drapes.

What regulatory dates should investors note related to MAGN's PFAS alternative?

The European Chemicals Agency expects final opinions on PFAS restrictions in 2026, and some U.S. state bans have compliance deadlines starting in 2025.

Will Magnera's MAGN product help healthcare providers comply with PFAS rules?

Magnera positions the product as a timely alternative to help providers and manufacturers reduce PFAS use and meet evolving rules.

Does Magnera quantify commercial contracts or revenue from the new MAGN solution?

No financial figures, contracts, or revenue impacts were disclosed in the announcement.

How can buyers contact Magnera about the PFAS-free nonwoven solution (MAGN)?

Buyers can contact Magnera via email at info@magnera.com or visit https://magnera.com/contact/.